Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Winner

Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.4%. By the end of trading, Bristol-Myers Squibb Company rose 32 cents (0.9%) to $34.29 on average volume. Throughout the day, 7.5 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.8 million shares. The stock ranged in a price between $34.10-$34.31 after having opened the day at $34.12 as compared to the previous trading day's close of $33.97. Other companies within the Health Care sector that increased today were: Medgenics ( MDGN), up 23.5%, Amyris ( AMRS), up 19.2%, Kindred Healthcare ( KND), up 18.8%, and Accelr8 Technology Corporation ( AXK), up 18.1%.

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $57.27 billion and is part of the drugs industry. The company has a P/E ratio of 15.7, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 3.7% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and nine rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Idera Pharmaceuticals ( IDRA), down 20.3%, NeurogesX ( NGSX), down 10.8%, Chemocentryx ( CCXI), down 8.5%, and Anthera Pharmaceuticals ( ANTH), down 7.5%, were all losers within the health care sector with Life Technologies ( LIFE) being today's health care sector loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Bristol-Myers 'Is Back' and Could Soar Another 14%

Bristol-Myers 'Is Back' and Could Soar Another 14%

These Were the 3 Hottest Stories on Wall Street Thursday

These Were the 3 Hottest Stories on Wall Street Thursday

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains